Abstract: A gear motor assembly includes a gearbox and a motor mounted to the gearbox. The gearbox includes a gear casing and a worm gear installed in the gear casing. The motor includes a stator, a rotor and brush gear. The rotor includes an shaft, a rotor core and a commutator fixed to the shaft. A worm integrally rotates with the shaft and is meshed with the worm gear. The brush gear includes multiple brushes slidably contacting the commutator, and multiple springs urging the corresponding brush towards the commutator. A lengthwise axis of the brush is inclined to a rotational axis of the commutator with a first angle between 75° to 87°.

Abstract: A cable assembly comprises: an insulative housing; a plurality of contacts received into the insulative housing; a spacer assembled to a rear end of the insulative housing; a wire management assembled to a rear end of the spacer, and a cable electrically connected to the rear ends of the plurality of contacts. The wire management defines a plurality of first and second channels formed on top surfaces. Each of second channel defines a rear inlet and two front outlets. The cable comprises several pairs of signal wires received into the corresponding second channels. Each differential pair of signal wires comprises two signal conductors, a grounding conductor and a shielding layer surrounding the two signal conductors and a grounding conductors. Two front ends of the two signal conductors are exposed out of the shielding layer and extending out of the wire management through two outlets.

Abstract: A flexible flat cable assembly comprises: a flexible flat cable having two opposite top and bottom surfaces, and defining a plurality of golden fingers exposed out of the top surface; and a base attached to the bottom surface of the flexible flat cable and defining a protecting portion formed on a front end thereof to shield front ends of the plurality of golden fingers.

Abstract: A motor drive device comprises a motor, a gearbox mounted to the motor and a control module. The gearbox comprises a gearbox housing that has an opening facing the motor. The motor has a shaft that extends into the gearbox housing through the opening to drive a worm gear of the gearbox. The control module has a PCB mounted to the gearbox and most of the PCB is accommodated in the opening of the gearbox housing. The PCB extends in a plane substantially parallel to the shaft.

Abstract: A power circuit, a converter structure and a wind power generation system thereof are disclosed. The power circuit includes a first converter having an AC input side and a DC output side, a second converter having a DC input side and an AC output side, and a DC bus storage unit electrically connected to the DC output side of the first converter and the DC input side of the second converter. A level number, a switching valve type and/or a circuit connection of the first converter are different from those of the second converter.

Abstract: An inductive electroacoustic transducer which includes a yoke, a magnetic circuit system disposing in the yoke, a vibration membrane which is driven by the magnetic circuit system, a cover coupled on one side of the yoke and it has a plurality of sound holes, and a circuit board which has a positive pole and a negative pole for importing acoustic electrical signals. The circuit board also has an inductive soldering disc and it is coupled to another side of the yoke. A portion of the yoke is connected to the inductive soldering disc with which it is conducted.

Abstract: An inductive electroacoustic transducer which includes a yoke, a magnetic circuit system disposing in the yoke, a vibration membrane which is driven by the magnetic circuit system, a cover coupled on one side of the yoke and it has a plurality of sound holes, and a circuit board which has a positive pole and a negative pole for importing acoustic electrical signals. The circuit board also has an inductive soldering disc and it is coupled to another side of the yoke. A portion of the yoke is connected to the inductive soldering disc with which it is conducted.

Abstract: The present invention relates to a composition comprising an immortalized cell line which is deficient in the expression of one or more gene(s) of the intrinsic apoptotic pathway, selected from the group consisting of Bax, Bak, and mixtures thereof. The present invention further relates to the product of a process for producing an immortalized mouse fibroblast cell line which is deficient in the expression of Bax, Bak, and mixtures thereof. Finally, the present invention relates to a method and a kit for identifying a compound or composition which induces or blocks the extrinsic apoptotic pathway.

Abstract: A gear motor assembly includes a gearbox, a motor mounted to the gearbox, a first damper and a second damper. The gearbox includes a gearing casing and a worm gear installed in the gear casing. The motor includes a stator and a rotor. The stator includes a housing. The rotor includes a motor shaft and a worm integrally rotating with the shaft. The shaft extends into the gear housing and the worm is meshed with the worm gear. The first damper is sandwiched between the gear casing and a first end of the shaft, eliminating end play between the shaft and the gear casing. The second damper is sandwiched between the motor housing and a second end of the shaft, eliminating end play between the shaft and the motor housing.

Abstract: A gear motor assembly includes a gearbox and a motor mounted to the gearbox. The gearbox includes a gear casing and a worm gear installed in the gear casing. The motor includes a stator, a rotor and brush gear. The rotor includes an shaft, a rotor core and a commutator fixed to the shaft. A worm integrally rotates with the shaft and is meshed with the worm gear. The brush gear includes multiple brushes slidably contacting the commutator, and multiple springs urging the corresponding brush towards the commutator. A lengthwise axis of the brush is inclined to a rotational axis of the commutator with a first angle between 75° to 87°.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Abstract: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or detecting anti-cancer agents.

Abstract: Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-?-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-?-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-?-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-?-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample.

Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Abstract: Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-?-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-?-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-?-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-?-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.